Clostridium difficile associated diarrhoea - tolevamer [ID378]
In development [GID-TAG389] Expected publication date: TBC
Search results
506 results
-
-
Lung cancer (non-small-cell, second line treatment) - vandetanib [ID46]
In development [GID-TAG405] Expected publication date: TBC
-
Cardiac transplantation (rejection) - everolimus [ID114]
In development [GID-TAG232] Expected publication date: TBC
-
Heart failure (acute decompensated) - nesiritide [ID384]
In development [GID-TAG376] Expected publication date: TBC
-
Atrial fibrillation - idraparinux sodium [ID375]
In development [GID-TAG383] Expected publication date: TBC
-
Venous thromboembolism (recurrent) - idraparinux sodium [ID395]
In development [GID-TAG384] Expected publication date: TBC
-
Psoriatic arthritis (moderate to severe) - leflunomide [ID391]
In development [GID-TAG385] Expected publication date: TBC
-
Diabetic retinopathy - ruboxistaurin [ID382]
In development [GID-TAG386] Expected publication date: TBC
-
Lung cancer (non-small-cell, advanced or metastatic maintenance treatment) - erlotinib (in combination with bevacizumab) [ID44]
In development [GID-TAG388] Expected publication date: TBC
-
Breast cancer (first line treatment) - sunitinib (in combination with a taxane) [ID58]
In development [GID-TAG391] Expected publication date: TBC
-
Juvenile idiopathic arthritis - adalimumab [ID385]
In development [GID-TAG400] Expected publication date: TBC
-
Atrial fibrillation - clopidogrel (in combination with aspirin) [ID95]
In development [GID-TAG416] Expected publication date: TBC
-
Leukaemia (chronic myeloid) - nilotinib (discontinued) [ID79]
In development [GID-TAG408] Expected publication date: 01 May 2011
-
Atrial fibrillation - ximelagatran [ID376]
In development [GID-TAG377] Expected publication date: TBC
-
Clinically isolated syndrome - beta interferons and glatiramer acetate [ID109]
In development [GID-TAG415] Expected publication date: TBC
-
Apalutamide for treating prostate cancer [ID1534]
In development [GID-TA10423] Expected publication date: 26 May 2021
-
Baricitinib for treating moderate to severe atopic dermatitis [ID1622]
In development [GID-TA10562] Expected publication date: 03 March 2021
-
Isatuximab with carfilzomib and dexamethasone for treating relapsed or refractory multiple myeloma [ID1620]
In development [GID-TA10491] Expected publication date: TBC
-
Galcanezumab for preventing cluster headache [ID1212]
In development [GID-TA10425] Expected publication date: 24 February 2021
-
Pembrolizumab with trastuzumab and chemotherapy for untreated HER2-positive advanced gastric or gastro-oesophageal junction cancer [ID3742]
In development [GID-TA10615] Expected publication date: TBC
-
Breast cancer (brain metastases) - etirinotecan pegol [ID881]
In development [GID-TA10066] Expected publication date: TBC
-
Empagliflozin for type 1 Diabetes Mellitus, adjunct to insulin ID1275
In development [GID-TA10375] Expected publication date: TBC
-
OTL-200 for treating metachromatic leukodystrophy [ID1666]
In development [GID-HST10028] Expected publication date: 13 August 2021
-
Atezolizumab with chemotherapy for neoadjuvant treatment of resectable early or locally advanced invasive triple-negative breast cancer [ID1574]
In development [GID-TA10531] Expected publication date: 15 December 2021
-
Spartalizumab with dabrafenib and trametinib for untreated BRAF V600 mutation-positive unresectable or metastatic melanoma [ID1668]
In development [GID-TA10577] Expected publication date: 21 April 2021
-
Ofatumumab for treating relapsing multiple sclerosis [ID1677]
In development [GID-TA10557] Expected publication date: TBC
-
PlGF-based testing to help diagnose suspected pre-eclampsia (Update of DG23)
In development [GID-DG10040] Expected publication date: 17 November 2021
-
Lenadogene nolparvovec for treating Leber's hereditary optic neuropathy [ID1410]
In development [GID-TA10391] Expected publication date: TBC
-
Esketamine for treating major depressive disorder in adults at imminent risk for suicide ID1604
In development [GID-TA10518] Expected publication date: TBC
-
Olaparib with bevacizumab for maintenance treatment of advanced ovarian, fallopian tube or primary peritoneal cancer [ID1652]
In development [GID-TA10526] Expected publication date: TBC
-
Lenvatinib with everolimus or pembrolizumab for untreated advanced renal cell carcinoma [ID3760]
In development [GID-TA10629] Expected publication date: TBC
-
Nivolumab in combination with chemotherapy for untreated advanced gastric or gastro-oesophageal junction cancer [ID1465]
In development [GID-TA10352] Expected publication date: 13 October 2021
-
Nivolumab for previously treated unresectable advanced oesophageal cancer [ID1249]
In development [GID-TA10222] Expected publication date: TBC
-
Daratumumab in combination for untreated systemic amyloid light-chain amyloidosis [ID3748]
In development [GID-TA10656] Expected publication date: 02 March 2022
-
SeHCAT (tauroselcholic [75 selenium] acid) for the investigation of bile acid diarrhoea
In development [GID-DG10039] Expected publication date: 17 November 2021
-
Mogamulizumab for previously treated T-cell leukaemia-lymphoma [ID1390]
In development [GID-TA10464] Expected publication date: TBC
-
Olaparib for previously treated, hormone-relapsed metastatic prostate cancer with homologous recombination repair gene mutations [ID1640]
In development [GID-TA10584] Expected publication date: 05 May 2021
-
Pertuzumab with trastuzumab emtansine for adjuvant treatment of early HER2-positive breast cancer [ID2711]
In development [GID-TA10591] Expected publication date: TBC
-
Avapritinib for treating unresectable or metastatic gastrointestinal stromal tumours [ID1626]
In development [GID-TA10523] Expected publication date: TBC
-
Alpelisib in combination with fulvestrant for treating advanced hormone-receptor positive, HER2-negative, PIK3CA-positive breast cancer [ID1412]
In development [GID-TA10398] Expected publication date: TBC
-
Quantitative faecal immunochemical tests to guide colorectal cancer pathway referral for people with a change in bowel habit or abdominal pain
In development [GID-DG10036] Expected publication date: TBC
-
Blinatumomab for treating Philadelphia-chromosome-positive relapsed or refractory acute lymphoblastic leukaemia [ID1008]
In development [GID-TA10119] Expected publication date: TBC
-
Durvalumab for untreated PD-L1-positive metastatic non-small-cell lung cancer [ID3762]
In development [GID-TA10633] Expected publication date: TBC
-
Atezolizumab in combination with platinum-based chemotherapy for untreated locally advanced or metastatic urothelial cancer [ID1206]
In development [GID-TA10202] Expected publication date: TBC
-
Secukinumab for treating moderate to severe plaque psoriasis in children and young people [ID1669]
In development [GID-TA10554] Expected publication date: 20 October 2021
-
Pembrolizumab with carboplatin and paclitaxel for untreated metastatic squamous non-small-cell lung cancer (CDF Review TA600) ID1683
In development [GID-TA10537] Expected publication date: TBC
-
Ruxolitinib for treating acute graft versus host disease refractory to corticosteroids in people aged 12 and over [ID2715]
In development [GID-TA10760] Expected publication date: TBC
-
Ruxolitinib for treating chronic graft versus host disease refractory to corticosteroids in people aged 12 and over [ID2716]
In development [GID-TA10761] Expected publication date: TBC
-
Relatlimab with nivolumab for treating advanced malignant melanoma after immunotherapy in people over 12 [ID1612]
In development [GID-TA10484] Expected publication date: TBC
-
Adults with complex needs: social work interventions including assessment, care management and support
In development [GID-NG10145] Expected publication date: 27 April 2022